Free tool
FAERS Monitor: Hemlibra
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761083 or its brand name (Hemlibra, Emicizumab). Reports on generic versions are filed under their own applications.
Reports
12,873
Serious
4,932
38% of reports
Hospitalization
2,071
Death reported
416
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- haemorrhage4,767
- haemarthrosis890
- off label use826
- no adverse event812
- fall705
- arthralgia539
- epistaxis437
- contusion427
- head injury382
- pain352
- muscle haemorrhage332
- limb injury257
- joint injury253
- injury241
- mouth haemorrhage240
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2011 | 1 |
| 2017 | 5 |
| 2018 | 159 |
| 2019 | 318 |
| 2020 | 527 |
| 2021 | 594 |
| 2022 | 973 |
| 2023 | 2,901 |
| 2024 | 3,633 |
| 2025 | 2,066 |
| 2026 | 1,696 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,041,286 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| haemarthrosisSignal | 890 | 180.0 | 168.3 | 142,622 |
| muscle haemorrhageSignal | 332 | 147.3 | 131.8 | 44,118 |
| haemorrhageSignal | 4,767 | 78.0 | 76.2 | 347,591 |
| mouth haemorrhageSignal | 240 | 55.3 | 48.6 | 12,320 |
| head injurySignal | 382 | 19.9 | 18.1 | 6,783 |
| joint injurySignal | 253 | 19.6 | 17.3 | 4,392 |
| limb injurySignal | 257 | 15.6 | 13.8 | 3,468 |
| epistaxisSignal | 437 | 9.6 | 8.7 | 3,349 |
| no adverse eventSignal | 812 | 7.4 | 6.9 | 4,468 |
| contusionSignal | 427 | 7.3 | 6.6 | 2,305 |
| injurySignal | 241 | 5.6 | 5.0 | 910 |
| fallSignal | 705 | 3.5 | 3.2 | 1,252 |
| arthralgiaSignal | 539 | 2.1 | 2.0 | 324 |
| off label use | 826 | 1.5 | 1.4 | 163 |
| pain | 352 | 0.9 | 0.8 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.